Gamida Cell Ltd

Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2020 Results - Earnings Call Transcript

Shares of Gamida Cell (NASDAQ:GMDA) moved higher by 1.6% in pre-market trading after the company reported Q2 results.

Gamida Cell: Q2 Earnings Insights

Gamida Cell (GMDA) will provide updates on its pipeline candidates when it releases second-quarter 2020 results.

Gamida Cell (GMDA) to Report Q2 Earnings: What's in Store?

Is  (GMDA) Outperforming Other Medical Stocks This Year?

Has Gamida Cell (GMDA) Outpaced Other Medical Stocks This Year?

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gamida Cell (GMDA) Upgraded to Strong Buy: Here's Why

Gamida Cell (GMDA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Gamida Cell (GMDA): Strong Industry, Solid Earnings Estimate Revisions

Atlas Air Worldwide

Cal-Maine Foods

Top Ranked Momentum Stocks to Buy for May 22nd

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2020 Results - Earnings Call Transcript

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q4 2019 Results - Earnings Call Transcript

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q3 2019 Results - Earnings Call Transcript

Gamida Cell has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Gamida Cell Enters Oversold Territory

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2019 Results - Earnings Call Transcript

News for Gamida Cell Ltd Stock (GMDA)